Wells Fargo & Company Legend Biotech Corp Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

A detailed history of Wells Fargo & Company transactions in Legend Biotech Corp stock. As of the latest transaction made, Wells Fargo & Company holds 14,939 shares of LEGN stock, worth $587,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,939
Previous 12,041 24.07%
Holding current value
$587,849
Previous $533,000 36.4%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$43.55 - $59.88 $126,207 - $173,532
2,898 Added 24.07%
14,939 $727,000
Q2 2024

Aug 13, 2024
SELL
$39.5 - $57.22 $118,895 - $172,232
-3,010 Reduced 20.0%
12,041 $533,000
Q1 2024

May 10, 2024
BUY
$55.06 - $69.99 $377,271 - $479,571
6,852 Added 83.57%
15,051 $844,000
Q4 2023

Feb 09, 2024
BUY
$57.25 - $69.74 $115,759 - $141,014
2,022 Added 32.73%
8,199 $493,000
Q3 2023

Nov 13, 2023
BUY
$63.16 - $76.5 $174,258 - $211,063
2,759 Added 80.72%
6,177 $414,000
Q2 2023

Aug 15, 2023
BUY
$46.28 - $75.01 $157,213 - $254,808
3,397 Added 16176.19%
3,418 $235,000
Q1 2023

May 12, 2023
BUY
$43.42 - $57.37 $477 - $631
11 Added 110.0%
21 $1,000
Q1 2022

May 16, 2022
SELL
$31.02 - $48.18 $41,194 - $63,983
-1,328 Reduced 99.25%
10 $0
Q4 2021

Feb 14, 2022
BUY
$41.14 - $56.98 $55,045 - $76,239
1,338 New
1,338 $62,000
Q4 2020

Feb 09, 2021
SELL
$25.8 - $32.39 $10,320 - $12,956
-400 Closed
0 $0
Q3 2020

Nov 05, 2020
BUY
$27.5 - $39.61 $11,000 - $15,844
400 New
400 $12,000

Others Institutions Holding LEGN

# of Institutions
216
Shares Held
77.9M
Call Options Held
412K
Put Options Held
387K
View Full List

About Legend Biotech Corp

LEGN Quotes by TradingView
  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.59B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email